Halozyme Therapeutics Reaches Analyst Target Price
November 15, 2016 at 09:51 AM EST
In recent trading, shares of Halozyme Therapeutics Inc (HALO) have crossed above the average analyst 12-month target price of $13.15, changing hands for $13.83/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..